The American Journal of Managed Care6mon
Advances in the Treatment of Demodex Blepharitis: Strategies for Improving Patient Outcomes
This article highlights clinical and economic factors associated with Demodex blepharitis as well as diagnostic complexities, limitations of traditional therapies, the safety and efficacy of the 1 ...
The Most Common Eyelid Disease You’ve Never Heard of Is Caused by Tiny Mites
Dealing with red, itchy eyelids? The culprit could be a common mite. This article is sponsored by XDEMVY. Dr. Watson is a ...
WebMD6y
Vitamins by Condition
Considering taking supplements to treat blepharitis? Below is a list of common natural remedies used to treat or reduce the symptoms of blepharitis. Follow the links to read common uses ...
The American Journal of Managed Care1mon
Discussing Key Updates in the Management of Patients with Demodex Blepharitis
An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment. Eric D. Donnenfeld, MD; underscores the ...
Business Insider9d
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
Groundbreaking data from the Ersa and Rhea clinical trials for the treatment of Demodex blepharitis (DB) in patients with Meibomian Gland Disease (MGD) further underscore the utility of XDEMVY broadly ...
Tarsus Pharmaceuticals: Strong Market Penetration and Promising Expansion into Ocular Rosacea
Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The ...
Nasdaq9d
Tarsus Pharmaceuticals Advances TP-04 for Ocular Rosacea Treatment, Phase 2 Study Set for 2025
This follows a successful 2024 for Tarsus, highlighted by the strong launch of XDEMVY, a treatment for Demodex blepharitis, generating over $113 million in sales. Tarsus is also pursuing ...